Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 1928 • 2019 ACR/ARP Annual Meeting
Identification of Immunological Processes Associated with the Response to Abatacept in Rheumatoid Arthritis Using Longitudinal Blood RNA-seq Analysis
Antonio Julià¹, Maria Lopez Lasanta ², Antonio Gómez ³, Irene Bonafonte ⁴, Raimon Sanmartí ⁵, Carlos Marras ⁶, José Manuel Pina ⁷, Susana Romero-Yuste ⁸, Raul Veiga ⁹, Pilar Navarro ⁹, Carmen Moragues Pastor ¹⁰, Silvia Martínez ¹¹, Francisco J. De Toro ¹², Amalia Sanchez ¹³, Dacia Cerdà ¹⁴, Alejandro Prada ¹⁵, Alba Erra ¹⁶, Jordi Monfort ¹⁷, A. Urruticoechea-Arana ¹⁸, Núria Palau ¹⁹, Raquel Lastra ²⁰, Raúl Tortosa ³, Andrea Pluma ²¹ and Sara Marsal ²², ¹Rheumatology Research Group, Vall d’Hebron Hospital Research Institute, Barcelona, Spain., Barcelona, Catalonia, Spain, ²Hospital Universitari Vall Hebrón, Barcelona, Barcelona, Catalonia, Spain, ³Hospital Vall d'Hebron, Barcelona, Barcelona, Spain, ⁴Vall Hebron Hospital Research Institute, Barcelona, Spain, ⁵Hospital Clínic, Barcelona, Barcelona, Spain, ⁶Hospital Universitario Virgen de la Arrixaca, Murcia, Murcia, Spain, ⁷Hospital de Barbastro, Huesca, Barbastro, Huesca, Spain, ⁸Complejo Hospitalario Universitario Pontevedra, Pontevedra, Galicia, Spain, ⁹Hospital Universitario Fuenlabrada, Fuenlabrada, Spain, ¹⁰Platò Hospital, Barcelona, Spain, Barcelona, Spain, ¹¹Hospital Universitari Mútua Terrassa, Terrassa, Spain, ¹²University Hospital A Coruña, A Coruña, Spain, ¹³Hospital Universitario Lucus Augusti, Lugo, Lugo, Spain, ¹⁴Hospital Moisès Broggi, Sant Joan Despí, Sant Joan Despí, Spain, ¹⁵Hospital Universitario Torrejón de Ardoz, Torrejón de Ardoz, Spain, ¹⁶Hospital Sant Rafael, Barcelona, Barcelona, Spain, ¹⁷Hospital del Mar, Barcelona, Spain, ¹⁸HU Can Misses, Ibiza, Spain, ¹⁹Hospital Vall Hebrón Barcelona, Barcelona, Spain, ²⁰Hospital Vall Hebron, Barcelona, Barcelona, Spain, ²¹Hospital Universitari Vall d'Hebron, Barcelona, Spain, ²²Vall d’Hebron Hospital, Barcelona, Catalonia, Spain
Background/Purpose: Abatacept (CTLA4-Ig) is an approved biological therapy for the treatment of rheumatoid arthritis (RA). Similar to other biological agents, most patients (50-60%) respond significantly…
Abstract Number: 2061 • 2019 ACR/ARP Annual Meeting
Association of Periodontitis with Rheumatological Disorders: NHANES III Analysis
Vivekanand Tiwari¹, Lawrence Brent ¹, Jasim Albandar ², Chinhua Hsiao ² and Shikha Shah ³, ¹Temple University, Philadelphia, PA, ²Kornberg School of Dentistry, Temple University, Philadelphia, PA, ³Levy Center for Oral Health Research, Philadelphia, PA
Background/Purpose: The association between periodontal diseases, smoking, and some systemic diseases such as diabetes mellitusis is well established. Periodontitis and rheumatological disorders share common immunological features and…
Abstract Number: 2253 • 2019 ACR/ARP Annual Meeting
Comparing Patient and Provider Perspectives on Long Term Biologic Use and Tapering in Stable, Well-Controlled Rheumatoid Arthritis
Patrick Webster¹, Nicole Wilson ², Christina Payne ¹, Kelly Shields ³ and Tarun Sharma ¹, ¹Allegheny Health Network, Pittsburgh, PA, ²Medicine Institute Research, Bioinformatics, Pittsburgh, PA, ³Highmark Data Science, Pittsburgh
Background/Purpose: The 2015 American College of Rheumatology (ACR) and 2013 European League Against Rheumatology (EULAR) guidelines for management of rheumatoid arthritis (RA) conditionally recommend consideration…
Abstract Number: 2313 • 2019 ACR/ARP Annual Meeting
Patients with Rheumatoid Arthritis Have a Higher Risk of Bipolar Disorder: A Systematic Review and Meta-analysis
Patompong Ungprasert¹, Nipith Charoenngam ² and Ben Ponvilawan ², ¹Cleveland Clinic, Cleveland, OH, Bangkok, Thailand, ²Mahidol University, Bangkok, Thailand
Background/Purpose: Patients with chronic autoimmune diseases may have a higher risk of psychiatric illness as a result of chronic neuro-inflammation and immune dysregulation. The current…
Abstract Number: 2331 • 2019 ACR/ARP Annual Meeting
Association of Rheumatoid Arthritis-related Autoantibodies with Pulmonary Function Test Abnormalities in a Prospective Rheumatoid Arthritis Registry
Sicong Huang¹, Xintong He ¹, Tracy J. Doyle ², Alessandra Zaccardelli ¹, Allison Marshall ¹, H. Maura Friedlander ³, Rachel Blaustein ³, Elisabeth Smith ³, Christine Iannaccone ¹, Taysir Mahmoud ³, Michael Weinblatt ¹, Paul Dellaripa ¹, Nancy Shadick ¹ and Jeffrey Sparks ¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Harvard Medical School, Boston, ³Brigham and Women's Hospital, Boston
Background/Purpose: Pulmonary involvement in rheumatoid arthritis (RA), such as bronchiectasis, bronchiolitis, pleuritis, or interstitial lung disease (ILD), is associated with high morbidity and mortality. Pulmonary…
Abstract Number: 2355 • 2019 ACR/ARP Annual Meeting
Antirheumatic Therapy Is Associated with Reduced Complement Activation in Rheumatoid Arthritis
Thao Nguyen¹, Ingrid Hokstad ², Gia Deyab ³, Tom Eirik Mollnes ⁴, Stefan Agewall ⁴, Morten Fagerland ⁴, Gro Eilertsen ⁵, Mark Feinberg ⁶, Knut Mikkelsen ², Øystein Førre ⁴ and Ivana Hollan ⁷, ¹Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ²Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Oppland, Norway, ³Innlandet Hospital Trust, Bærum, Akershus, Norway, ⁴Oslo University Hospital, Oslo, Norway, ⁵The Artic University of Norway, Tromsø, Norway, ⁶Harvard Medical School and Brigham and Women´s Hospital, Boston, Boston, MA, ⁷Lillehammer Hospital for Rheumatic Diseases and Brigham and Women’s Hospital, Boston, Lillehammer, Oppland, Norway
Background/Purpose: Inflammation and immune dysregulation appear to significantly contribute to increased risk of cardiovascular disease (CVD) in rheumatoid arthritis (RA). The complement system is a…
Abstract Number: 2378 • 2019 ACR/ARP Annual Meeting
Comparative Analysis of Clinical, Laboratory and Therapeutic Strategies Among Blacks with Rhupus, SLE and RA
Naureen Kabani¹, Joshy Pathiparampil ², Madina Abduraimova ², Latoya Freeman-Beman ², Sima Terebelo ¹, Abida Hasan ¹, Christon Grant ¹, James Salgado ¹, Manjeet Bhamra ¹, Tracian James-Goulbourne ¹, Khabbab Amin ¹, Yamen Homsi ³ and Isabel McFarlane ², ¹SUNY Downstate Medical Center, Brooklyn, ²SUNY Downstate Medical Center, Brooklyn, NY, ³NYU Langone Medical Center, Brooklyn, NY
Background/Purpose: Rhupus is the overlap of SLE and RA. While a few studies have been conducted among Rhupus patients, no studies have focused on Black…
Abstract Number: 2415 • 2019 ACR/ARP Annual Meeting
Evaluation of Pharmacokinetics and Immunogenicity Following Subcutaneous Administration of Abatacept in Primary Sjogren ’s Syndrome (pSS) and RA Patients
Yash Gandhi¹, Mehmooda Shaikh ², Blisse Vakkalagadda ¹, Grigor Abelian ¹, Neelanjana Ray ¹, Robert Wong ¹ and Bindu Murthy ¹, ¹Bristol-Myers Squibb, Princeton, ²Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Abatacept (ABA) has proven efficacy in autoimmune diseases and is being evaluated in pSS. The purpose of this investigation was to evaluate the pharmacokinetics…
Abstract Number: 2849 • 2019 ACR/ARP Annual Meeting
Radiographic Progression During a 10-Year Follow-Up : Results from the French Cohort ESPOIR
Joanna Kedra¹, David Hajage ², Alexandre Lafourcade ², Bernard Combe ³, Maxime Dougados ⁴ and Bruno Fautrel ⁵, ¹Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), UMR S1136, Paris France, Paris, France, ²Biostatistics, Public Health and Medical Information department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France, Paris, France, ³CHU Montpellier, Montpellier University, Montpellier, France, ⁴Cochin Hospital, Paris, France, ⁵Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France
Background/Purpose: In early arthritis, identification of patients at risk of developing joint damage is an important issue. In rheumatoid arthritis (RA), the rate of progression…
Abstract Number: 4 • 2019 ACR/ARP Annual Meeting
AMP Deaminase 2 Surface Expression Counteracting CD73-Driven Generation of Anti-Inflammatory Extracellular Adenosine
Lisa Ehlers¹, Aditi Kuppe ¹, Cindy Strehl ¹, Marieluise Kirchner ², Frank Buttgereit ³ and Timo Gaber ¹, ¹Charite University Hospital Berlin, Berlin, Germany, ²Max Delbrück Center for Molecular Medicine, BIH Core Facility Proteomics, Berlin, Germany, ³Charité-Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Adenosine and its nucleotides represent crucial immunomodulators in the extracellular environment. ATP and ADP are released from stressed cells in states of inflammation, whereas…
Abstract Number: 57 • 2019 ACR/ARP Annual Meeting
Endothelial Progenitor Cells in the Pathophysiology of Interstitial Lung Disease Associated with Rheumatoid Arthritis
Veronica Pulito-Cueto¹, Sara Remuzgo-Martínez ¹, Fernanda Genre ¹, Leticia Lera-Gomez ¹, Veronica Mijares ¹, Pilar Alonso Lecue ², Victor Manuel Mora Cuesta ², David Iturbe ³, Sonia M. Fernández Rozas ², Ricardo Blanco ⁴, Alfonso Corrales ¹, Jose Manuel Cifrian Martínez ², Raquel López-Mejías ¹ and Miguel A Gonzalez-Gay ⁴, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, ²Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL; and Pneumology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain, Santander, Spain, ³Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain; and Pneumology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain, Santander, Spain, ⁴Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) is one of the most significant comorbidities that contributes to the increased mortality observed in patients with rheumatoid arthritis (RA)…
Abstract Number: 186 • 2019 ACR/ARP Annual Meeting
Asthma, Chronic Obstructive Pulmonary Disease, and Subsequent Risk for Incident Rheumatoid Arthritis Among Women: A Prospective Cohort Study
Julia Ford¹, Xinyi Liu ¹, Su H. Chu ², Bing Lu ¹, Michael Cho ¹, Edwin Silverman ¹, Karen Costenbader ¹, Carlos Camargo ³ and Jeffrey Sparks ¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Massachusetts General Hospital, Boston, MA
Background/Purpose: While RA patients are known to have excess respiratory morbidity and mortality, less is known about the role of chronic respiratory diseases in the…
Abstract Number: 276 • 2019 ACR/ARP Annual Meeting
Effectiveness of Screening by Nurse with Predetermined Questionnaire on Infections Before Administration of Intravenous Biologics in Patients with Rheumatoid Arthritis
Sayaka Furukawa¹, Sho Fukui ¹, Sakura Tamaki ², Tomoko Nakasone ³ and Masato Okada ⁴, ¹St.Luke's International Hospital, Chuo-ku, Tokyo, Japan, ²St. Luke's International Hospital, Chuo-ku, Japan, ³St. Luke's International Hospital, Chuo-ku, Tokyo, Japan, ⁴St. Luke's International Hospital, Tokyo, Japan
Background/Purpose: Biologics are widely used as treatment for rheumatoid arthritis (RA), and pre-administration screening of active infection is imperative for the safety use. There is…
Abstract Number: 446 • 2019 ACR/ARP Annual Meeting
High MDHAQ/RAPID3 (Multidimensional Health Assessment Questionnaire/Routine Assessment of Patient Index Data) Scores in RA Patients Who Have Depression According to a Screening Questionnaire
Rosa Morlà¹, Mariam Riad ², Raul Castellanos-Moreira ³, Virginia Ruiz-Esquide ⁴, Raimon Sanmarti ⁵, Jose Gomez-Puerta ⁶, Theodore Pincus ² and Isabel Castrejon ², ¹Rheumatology Unit, Xarxa Sanitaria Santa Tecla, Tarragona. Rheumatology, Fundacio Clinic, Barcelona, Barcelona, Spain, ²Division of Rheumatology, Rush University Medical Center, Chicago, IL, ³Rheumatology Department. Hospital Clínic Barcelona, Barcelona, Catalonia, Spain, ⁴Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Catalonia, Spain, ⁵Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain, ⁶Servei de Rheumatologia, Hospital Clinic Universtari, Barcelona, Barcelona, Catalonia, Spain
Background/Purpose: Depression in rheumatoid arthritis (RA) patients may be pre-existent, amplified, or may develop after the onset of RA1. The Patient Health Questionnaire (PHQ9) is…
Abstract Number: 472 • 2019 ACR/ARP Annual Meeting
Sleep Quality in Women with Rheumatoid Arthritis Is Associated with Disease Activity and Depressive Symptoms
Deborah Da Costa¹, Teresa Szlachetka ² and Diane Lacaille ³, ¹McGill University, Montreal, QC, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Canada and University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Sleep disturbances, including difficulty initiating sleep, maintaining sleep, and/or early morningawakenings are prevalent in persons with rheumatoid arthritis (RA) and can significantly impact quality…

« Previous Page
1
…
5
6
7
8
9
…
56
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.